Prednisolone Versus Colchicine for Acute Gout in Primary Care
NCT ID: NCT05698680
Last Updated: 2025-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
314 participants
INTERVENTIONAL
2023-01-18
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This pragmatic, prospective, double-blind, parallel-group, randomized, non-inferiority trial will investigate whether prednisolone (treatment drug) is comparable or only acceptably worse than treatment with colchicine (comparison drug) in patients presenting with acute gout. Patients presenting with acute gout to their general practitioners in 60 practices across 3 university sites (Greifswald, Göttingen, and Würzburg) will be invited to participate. Patients often excluded by previous studies due to contraindications with naproxen will also be able to participate. The investigators will compare the absolute levels of the most severe pain on day 3 (in the last 24 hours) measured with an 11-item numerical rating scale as the primary endpoint. Day 0 is the day patients take their study medication for the first time. They are then asked to fill out a study diary at the same time each day to quantify their pain. Pain scores will then be used as comparison between the two medications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MPC-004 for the Treatment of an Acute Gout Flare
NCT00506883
Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
NCT03933007
Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients
NCT05006001
Colchicine Or Naproxen Treatment for ACute gouT
NCT01994226
Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation
NCT04844814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Gout is one of the most common rheumatic diseases, affecting 3-6% of men and 1-2% of women in western countries. Due to the severe pain and impaired quality of life, the individual burden of disease during an acute gout attack is very high. Currently, there are several approved medications available for the treatment of acute gout attacks. The EULAR (European League Against Rheumatism) guideline recommends colchicine as the drug of first choice for acute gout attacks. But according to it, non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids can also be used. In contrast, DEGAM (German Society for General Medicine and Family Medicine) recommends using prednisolone.
Most commonly, gout attacks are treated in general practices. However, studies on the treatment of acute gout attacks have so far been conducted mainly in specialised centres, and thus in a selective patient group. The gold standard for the diagnosis of gout in rheumatology centres is the detection of monosodium urate crystals in aspirated joint fluid. In primary care, however, the diagnosis of gout is made on the basis of clinical symptoms alone. Because of the risk of injury and infection, joint puncture is not usually performed on patients in a general practice setting.
Prednisolone and low-dose colchicine were selected for the study due to a high prevalence of patients with contraindications to NSAIDs, including, cardiovascular disease, oral anticoagulation, chronic kidney disease or a history of gastrointestinal disease. Approximately 20-30% of patients with gout are poorly suited for NSAID administration and in previous studies, those patients were excluded.
RESEARCH QUESTION:
This non-inferiority trial is going to investigate whether prednisolone (treatment drug) is comparable or only acceptably worse than treatment with colchicine (comparator drug). Both treatments will be compared on the basis of the absolute pain scores achieved on day 3 of follow-up.
Unlike most studies conducted in tertiary care centres, this study is going to be set in primary care. The dosage of the study's medications will be according to the recommendations of the EULAR and DEGAM guidelines. Both drugs are in tablet form. Since a preference of the treating physicians regarding the use of prednisolone or colchicine is suspected, the study will be conducted in a double-blinded manner. Due to the different intake regimen, placebos will be used in addition to the effective medications (double-dummy method).
DUAL ENERGY COMPUTED TOMOGRAPHY:
The dual energy computed tomography (DECT) is able to detect monosodium urate crystals. The amount of monosodium urate crystals in the joint (volume) is an indicator of disease burden and can also be used to make treatment decisions regarding uric acid-lowering therapy (ULT) to avoid the occurrence of potential future gout attacks. Although imaging techniques, such as DECT, show promise in classifying symptomatic gout, studies to date are small and mainly involve people with long-standing, established disease from a hospital setting. In those with the first acute gout attack, diagnostic sensitivity ranges from 35.7 % to 61.5 %.
Due to the unclear diagnostic sensitivity in first attacks, the DECT examination will not be mandatory in the present study. It will be offered to all participants as optional. About 10% of the participants are expected to have a gout attack in the hand. Since the joints of the feet are the main site of manifestation of acute gout attacks, crystal deposits in the feet are also expected in these study participants. In order to ensure comparability of the volume measurement, the dual energy CT examination is therefore limited to the feet.
The aim of the dual energy CT examination is to describe the frequency and volume of monosodium urate crystals in patients with gout in primary care. In a sensitivity analysis, the primary endpoint in patients with positive DECT findings will be analysed. Furthermore, the association between the duration of gout diagnosis and crystal volume as a marker for disease burden will be investigated. The investigation of the frequency and volume of monosodium urate crystals provides the basis for the design of further studies on the usefulness of DECT for the indication and monitoring of uric acid-lowering therapies in primary care.
STUDY PROCEDURE:
During the study, the participants will attend their General Practitioner's practice twice (baseline and one-off on day 6-8), as well as, an optional visit for a DECT at the university medical centre in the local region (Greifswald or Göttingen; day 7-13) and a one-off telephone interview on day 27-34. The study period for the individual participant will be 4 weeks.
On day 0 (day of first presentation at the general practice), patients with an acute gout attack in the hand or foot present to their general practitioner. If the diagnosis of gout is confirmed and patients are eligible for participation in the study, they will be consented and randomly assigned to one of two treatment groups. While patient group 1 is treated with prednisolone for 5 days, patient group 2 receives colchicine for 5 days. So that neither the patient nor the general practitioner knows the allocation, both treatment groups also receive a placebo (dummy medication). A laboratory test will also be performed to determine serum uric acid levels, as well as, inflammatory markers and renal function. The aim of blood collection and determination of laboratory parameters is to descriptively describe the patient population and to perform subgroup analyses with regard to the primary endpoint.
During days 1 to 6, patients are requested to complete a patient diary. The primary and secondary endpoints (pain, joint swelling, joint tenderness) and, if further analgesia is needed, the use of additional pain medication will be recorded in the diary. Participants who have a blood pressure monitor will be asked to measure and record their blood pressure daily. On day 6, the patients are also asked to assess potential functional limitations caused by the gout attack and to give a global assessment of the treatment success.
After one week, patients return for their follow-up visit (visit 2) to their general practitioners. They are examined again and are asked to return their study diary and any remaining medication packets.
After 4 weeks, the patients will be contacted by telephone by our study nurses and asked about the clinical course of their gout attack (recurrence of an acute gout attack, further treatment, duration of incapacity to work, adverse events). The telephone call lasts about 15 minutes.
In addition, study participants will receive the optional offer to have a one-time dual-energy CT examination of their feet on days 7-13 to check for the presence of uric acid crystals. Imaging of both feet using a Siemens Dual Source SOMATOM Definition Flash or SOMATOM Force will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
According to the guidelines of the German Society of General Medicine (DEGAM), the decision to start gout treatment is made clinically. As this is a pragmatic study, eligibility will be determined during a routine clinical examination. The clinical diagnosis is made without new laboratory tests, joint puncture with synovial analysis or imaging.
314 patients with an acute gout attack are going to be recruited in 60 General Practitioner's practices across 3 university sites (Greifswald, Göttingen, and Würzburg). All study participants receive active treatments, but are randomised into either the prednisolone group (treatment group) or the colchicine group (comparison group). The study lasts 4 weeks for each participant.
TREATMENT
QUADRUPLE
As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo. Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prednisolone 30mg (Day 0-4)
As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste.
The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 150 mg for prednisolone.
Prednisolone 30 mg Tablet
See treatment arm "Prednisolone"
Colchicine 1.5 mg (Day 0), 1.0 mg (Day 1-4)
As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo.
The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 5.5mg for colchicine.
Colchicine 0.5 mg Oral Tablet
See treatment arm "Colchicine"
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prednisolone 30 mg Tablet
See treatment arm "Prednisolone"
Colchicine 0.5 mg Oral Tablet
See treatment arm "Colchicine"
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of acute attack of gout (symptoms: pain, swelling, tenderness, redness or local hyperthermia).
* Acute pain in hand or foot (podagra, chiragra)
* The onset of pain was no more than 2 days ago (e.g., presentation on Monday afternoon, onset of pain on Saturday morning)
* Willingness to participate in the study and ability to give written informed consent.
Exclusion Criteria
* Known intolerance to the placebo (e.g. lactose intolerance).
* Existing (or less than 2 weeks ago) oral treatment with corticosteroids or colchicine.
* Known chronic kidney disease (CKD stage 4 or greater) or an available value of estimated glomerular filtration rate (eGFR) \< 30ml/min/1.73 m².
* Known haematopoietic disorder or available values of platelets \< 30,000 µl or leucocytes \< 4000 µl, or Hb \<5 mmol/l/ or 8 g/dl
* Uncontrolled high blood pressure (systolic blood pressure permanently above 160 mmHg).
* Known liver cirrhosis or severe liver disease or available liver enzymes results (ie. Serum Glutamate Oxalate Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase(SGPT)) being elevated by more than twice the respective reference range
* Known current gastric or duodenal ulcer (diagnosed in the last 4 weeks)
* Current chemotherapy or chemotherapy completed less than 3 months ago
* Known HIV infection
* Solid organ transplant with immune suppression
* Desire to have children within the next 6 months in both men and women
* Existing pregnancy or breastfeeding
* Participation in other studies according to the German Medicines Act in the last 3 months
* Participation in the COPAGO study with past gout attack
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Göttingen
OTHER
Wuerzburg University Hospital
OTHER
University Medicine Greifswald
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sylvia Stracke
Role: PRINCIPAL_INVESTIGATOR
University Medicine Greifswald
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arztpraxis Burgtorstr. 2
Ittlingen, Baden-Wurttemberg, Germany
Hausarztpraxis Neckarsteinacher Str. 22
Neckargemünd, Baden-Wurttemberg, Germany
Hausarztpraxis Kleinfeldlein 3
Bad Bocklet, Bavaria, Germany
Hausarztpraxis Kapellenstraße 3
Bad Kissingen, Bavaria, Germany
Hausarztpraxis Ludwigstraße 18
Bad Kissingen, Bavaria, Germany
Hausarztpraxis Goethestraße 15 G
Bad Neustadt an der Saale, Bavaria, Germany
Hausarztpraxis Ahornstraße 1
Bischofsheim, Bavaria, Germany
Hausarztpraxis Mechenharder Straße 174
Erlenbach am Main, Bavaria, Germany
Hausarztpraxis Hauptstraße 12
Gössenheim, Bavaria, Germany
Hausarztpraxis Bahnhofstraße 24
Hammelburg, Bavaria, Germany
Hausarztpraxis Torgraben 3
Haßfurt, Bavaria, Germany
Hausarztpraxis Kaiserstraße 43
Kitzingen, Bavaria, Germany
Hausarztpraxis Rathausstraße 31
Leinach, Bavaria, Germany
Hausarztpraxis Herrngasse 11 A
Rimpar, Bavaria, Germany
Hausarztpraxis Spitalstr. 9
Schweinfurt, Bavaria, Germany
Hausarztpraxis Sulzdorfer Straße 6a
Stadtlauringen, Bavaria, Germany
Hausarztpraxis Dorfgraben 2a
Würzburg, Bavaria, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany
Hausarztpraxis Moltkestraße 5
Würzburg, Bavaria, Germany
Hausarztpraxis Point 3
Zellingen, Bavaria, Germany
Hausarztpraxis Wissmannstraße 14
Bad Lauterberg im Harz, Lower Saxony, Germany
Hausarztpraxis Hoher Weg 17
Bilshausen, Lower Saxony, Germany
Hausarztpraxis Bohlendamm 2
Gleichen, Lower Saxony, Germany
Hausarztpraxis Liererstr. 28
Goslar, Lower Saxony, Germany
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany
Hausarztpraxis Ewaldstr. 40a
Göttingen, Lower Saxony, Germany
Hausarztpraxis Hennebergstr. 14a
Göttingen, Lower Saxony, Germany
Hausarztpraxis Backhausstraße 21
Göttingen, Lower Saxony, Germany
Hausarztpraxis Godehardtstraße 26
Göttingen, Lower Saxony, Germany
Hausarztpraxis Professor-Eberlein-Str. 6
Hannoversch Münden, Lower Saxony, Germany
Hausarztpraxis Steinstraße 19
Hannoversch Münden, Lower Saxony, Germany
Hausarztpraxis Vor dem Tore 2
Hardegsen, Lower Saxony, Germany
Hausarztpraxis Eckert Osteroder Str. 9
Herzberg am Harz, Lower Saxony, Germany
Hausarztpraxis Poppe Osteroder Str. 9
Herzberg am Harz, Lower Saxony, Germany
Hausarztpraxis Hauptstraße 34
Krebeck, Lower Saxony, Germany
Hausarztpraxis Neue Straße 22
Moringen, Lower Saxony, Germany
Hausarztpraxis Bahnhofstraße 6
Scheden, Lower Saxony, Germany
Hausarztpraxis Kampstr. 32
Seesen, Lower Saxony, Germany
Hausarztpraxis Bluthsluster Straße 2
Anklam, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Am Westhafen 1
Barth, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Schlossstraße 43
Dargun, Mecklenburg-Vorpommern, Germany
Krankenhaus Universitätsmedizin Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Am Mühlentor 5
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Anklamer Straße 66
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Lange Straße 53
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Markt 1
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Ernst-Thälmann-Ring 66
Greifswald, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Schulstraße 1a
Groß Kiesow, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Pommersche Straße 18
Gützkow, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Prohner Straße 43
Klausdorf, Mecklenburg-Vorpommern, Germany
Hausarztpraxis August-Levin-Straße 22c
Loitz, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Bahnhofstraße 16
Lübstorf, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Oberreihe 41
Lühmannsdorf, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Juri-Gagarin-Ring 24
Neubrandenburg, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Störstraße 2
Plate, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Werdohler Straße 3
Stavenhagen, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Marienstraße 2-4
Stralsund, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Dorfstraße 57
Trent, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Birkenweg 5
Trinwillershagen, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Otto-Lilienthal-Straße 3
Trollenhagen, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Ueckerstraße 48
Ueckermünde, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Lange Straße 55
Waren, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Wilhelmstraße 3
Wolgast, Mecklenburg-Vorpommern, Germany
Hausarztpraxis Lambertweg 6
Höxter, North Rhine-Westphalia, Germany
Hausarztpraxis Straße der Einheit 56
Uder, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Til Uebel, Dr. med.
Role: primary
Til Uebel, Dr. med.
Role: primary
Stephan Stoll, Dr. med.
Role: primary
Michael Brendler
Role: primary
Ralph Brath, Dr. med.
Role: primary
Claudia Pladek-Weier
Role: primary
Martin Wünsch, Dr. med.
Role: primary
Detlef Schmitz, Dr. med.
Role: primary
Timo Jung
Role: primary
Andreas Langeheinecke, Dr. med.
Role: primary
Carolin Fritzenkötter, Dr. med.
Role: primary
Konrad Mittenzwei
Role: primary
Stefan Heßdörfer, Dr. med.
Role: primary
Johannes Schmitt
Role: primary
Silke Daci
Role: primary
Julia Treiber, Dr. med.
Role: primary
Hans-Jörg Hellmuth, Dr. med.
Role: primary
Nandini Jain, Dr. med.
Role: primary
Petra Schlegel, Dr. med.
Role: primary
Cordula Sachse-Seeboth, Dr. med.
Role: primary
Karen Lodhia, Dr. med.
Role: primary
Helia Beulshausen
Role: primary
Ute Heskamp, Dr. med.
Role: primary
Martin Andreas Lang, Dr. med.
Role: primary
Michal Olszewski, Dr. med.
Role: primary
Wolfgang Keske, Dr. med.
Role: primary
Sarah Schilling, Dr. med.
Role: primary
Carsten Hafer, Dr. med.
Role: primary
Donata Suwelack
Role: primary
Matthias Löber, Dr. med.
Role: primary
Moritz Eckert
Role: primary
Henning Poppe
Role: primary
Stephan Geibel, Dr. med.
Role: primary
Petra Kamin
Role: primary
Anne Hafer, Dr. med.
Role: primary
Jan Sturm, Dr. med.
Role: primary
Kristin Runge, Dr. med.
Role: primary
Martin Domnick, Dr. med.
Role: primary
Mahmoud Sannan
Role: primary
Matthias Herberg, Dr. med.
Role: primary
Jens Thonack, Prof. Dr. med.
Role: primary
Hanna Wilfert, Dr. med.
Role: primary
Annika Kohlhase, Dr. med.
Role: primary
Aniela Angelow, Dr. med.
Role: primary
Mirjam Mittelstädt
Role: primary
Christian Ottl, Dr. med.
Role: primary
Florian Stockinger, Dr.med.univ.
Role: primary
Rebekka Preuß, Dr. med.
Role: primary
Alexander Dagge, Dr. med.
Role: primary
Mirjam Mittelstädt
Role: primary
Thomas Hannemann, Dr. med.
Role: primary
Petra Pöhler
Role: primary
Jan Lichte, Dr. med.
Role: primary
Annegret Kuwert, Dr. med.
Role: primary
Thomas Harnisch
Role: primary
Jan Eska, Dr. med.
Role: primary
Thomas Hanff
Role: primary
Andrea Mossner, Dr. med.
Role: primary
Christian Flamm, Dr. med.
Role: primary
Gero Kärst, Dr. med.
Role: primary
Regina Beverungen, Dr. med.
Role: primary
David Baudisch
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Richter A, Truthmann J, Hummers E, Pereira JFM, Gagyor I, Schuster F, Witte A, Bohm S, Greser A, Kamin P, Stracke S, Dorr M, Bulow R, Engeli S, Chenot JF, Ittermann T. Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial. Trials. 2024 Apr 3;25(1):229. doi: 10.1186/s13063-024-08066-0.
Truthmann J, Freyer Martins Pereira J, Richter A, Schuster F, Witte A, Bohm S, Greser A, Kamin P, Stracke S, Dorr M, Bulow R, Engeli S, Gagyor I, Hummers E, Chenot JF. Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design. Trials. 2023 Oct 5;24(1):643. doi: 10.1186/s13063-023-07666-6.
Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016 Oct 22;388(10055):2039-2052. doi: 10.1016/S0140-6736(16)00346-9. Epub 2016 Apr 21.
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421-6. doi: 10.1016/0002-9343(87)90441-4.
Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017 Jul;76(7):1289-1294. doi: 10.1136/annrheumdis-2016-210588. Epub 2017 Jan 25.
ten Klooster PM, Vonkeman HE, Voshaar MA, Bode C, van de Laar MA. Experiences of gout-related disability from the patients' perspective: a mixed methods study. Clin Rheumatol. 2014 Aug;33(8):1145-54. doi: 10.1007/s10067-013-2400-6.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev. 2014 Aug 15;(8):CD006190. doi: 10.1002/14651858.CD006190.pub2.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010 Jun;48(5):407-14. doi: 10.3109/15563650.2010.495348.
Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327.
Engel B, Prautzsch H. [Acute gout in primary care]. 2013. Available from: https://www.awmf.org/uploads/tx_szleitlinien/053_032bl_S1_akute_Gicht_2014-05.pdf
van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewe RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2.
Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140-6736(08)60799-0.
McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. Colchicine for acute gout. Cochrane Database Syst Rev. 2021 Aug 26;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3.
Janssens HJEM, Fransen J, Janssen M, Neogi T, Schumacher HR, Jansen TL, Dalbeth N, Taylor WJ. Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology (Oxford). 2017 Aug 1;56(8):1335-1341. doi: 10.1093/rheumatology/kex164.
Dalbeth N, Schumacher HR, Fransen J, Neogi T, Jansen TL, Brown M, Louthrenoo W, Vazquez-Mellado J, Eliseev M, McCarthy G, Stamp LK, Perez-Ruiz F, Sivera F, Ea HK, Gerritsen M, Scire CA, Cavagna L, Lin C, Chou YY, Tausche AK, da Rocha Castelar-Pinheiro G, Janssen M, Chen JH, Cimmino MA, Uhlig T, Taylor WJ. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1894-1898. doi: 10.1002/acr.22896. Epub 2016 Oct 28.
Roddy E, Clarkson K, Blagojevic-Bucknall M, Mehta R, Oppong R, Avery A, Hay EM, Heneghan C, Hartshorne L, Hooper J, Hughes G, Jowett S, Lewis M, Little P, McCartney K, Mahtani KR, Nunan D, Santer M, Williams S, Mallen CD. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2020 Feb;79(2):276-284. doi: 10.1136/annrheumdis-2019-216154. Epub 2019 Oct 30.
Richette P, Flipo RN, Patrikos DK. Characteristics and management of gout patients in Europe: data from a large cohort of patients. Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):630-9.
Nyberg F, Horne L, Morlock R, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Chevalier P. Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. Adv Ther. 2016 Jul;33(7):1180-98. doi: 10.1007/s12325-016-0346-1. Epub 2016 May 26.
Johnson TR. Dual-energy CT: general principles. AJR Am J Roentgenol. 2012 Nov;199(5 Suppl):S3-8. doi: 10.2214/AJR.12.9116.
Dalbeth N, Doyle AJ. Imaging tools to measure treatment response in gout. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i27-i34. doi: 10.1093/rheumatology/kex445.
Pascart T, Grandjean A, Capon B, Legrand J, Namane N, Ducoulombier V, Motte M, Vandecandelaere M, Luraschi H, Godart C, Houvenagel E, Norberciak L, Budzik JF. Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare. Arthritis Res Ther. 2018 Sep 17;20(1):210. doi: 10.1186/s13075-018-1714-9.
Uhlig T, Eskild T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, Dalbeth N, Hammer HB. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology (Oxford). 2022 Apr 18;61(SI):SI81-SI85. doi: 10.1093/rheumatology/keab533.
Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, Schumacher HR, Dalbeth N. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015 Oct;74(10):1868-74. doi: 10.1136/annrheumdis-2014-205431. Epub 2014 Jun 10.
Choi HK, Burns LC, Shojania K, Koenig N, Reid G, Abufayyah M, Law G, Kydd AS, Ouellette H, Nicolaou S. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis. 2012 Sep;71(9):1466-71. doi: 10.1136/annrheumdis-2011-200976. Epub 2012 Mar 2.
Glazebrook KN, Kakar S, Ida CM, Laurini JA, Moder KG, Leng S. False-negative dual-energy computed tomography in a patient with acute gout. J Clin Rheumatol. 2012 Apr;18(3):138-41. doi: 10.1097/RHU.0b013e318253aa5e.
Huppertz A, Hermann KG, Diekhoff T, Wagner M, Hamm B, Schmidt WA. Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int. 2014 Jun;34(6):763-71. doi: 10.1007/s00296-014-2979-1. Epub 2014 Mar 12.
Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz WB 3rd, Michet CJ, Veetil BM, Davis JM 3rd, Mason TG 2nd, Warrington KJ, Ytterberg SR, Matteson EL, Crowson CS, Leng S, McCollough CH. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015 Jun;74(6):1072-7. doi: 10.1136/annrheumdis-2013-205095. Epub 2014 Mar 25.
Jia E, Zhu J, Huang W, Chen X, Li J. Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout. Clin Rheumatol. 2018 Mar;37(3):773-777. doi: 10.1007/s10067-017-3753-z. Epub 2017 Aug 12.
Related Links
Access external resources that provide additional context or updates about the study.
Information about the study for patients and treating physicians in German
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01KG2022
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2024-514738-18-00
Identifier Type: CTIS
Identifier Source: secondary_id
2021-005556-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
202102COPAGO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.